SCHEMBL7475848

SCHEMBL7475848

CC(C)(C)OC(=O)C[C@H](CCCOCc1cccc(Cl)c1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.41
PKM P14618 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
FFAR1 O14842 1/20 0.39
PPARA Q07869 1/20 0.38
MAOB P27338 3/20 0.38
MAOA P21397 2/20 0.38
NR4A2 P43354 1/20 0.38
MMP1 P03956 2/20 0.38
MMP3 P08254 2/20 0.38
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
TACR1 P25103 2/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7477211 0.97 L3MBTL1 (0.42) CTSLPKML3MBTL1RXRARXRB
SCHEMBL15684087 0.87 L3MBTL1 (0.51) L3MBTL1PPARAMMP1MMP3MMP9
SCHEMBL14243701 0.87 L3MBTL1 (0.51) L3MBTL1PPARAMMP1MMP3MMP9
SCHEMBL7422742 0.84 L3MBTL1 (0.53) L3MBTL1PPARAMMP1MMP3MMP9
SCHEMBL1915662 0.83 CTSL (0.51) CTSLPKMPPARA
SCHEMBL1915659 0.83 CTSL (0.51) CTSLPKMPPARA
SCHEMBL2410580 0.81 PPARA (0.49) L3MBTL1PPARAMMP1MMP3MMP9
SCHEMBL17756152 0.81 PPARA (0.49) L3MBTL1PPARAMMP1MMP3MMP9
SCHEMBL2410585 0.81 PPARA (0.49) L3MBTL1PPARAMMP1MMP3MMP9
SCHEMBL17755918 0.79 L3MBTL1 (0.46) L3MBTL1PPARAMMP1MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020040002-A1 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor ZENECA LIMITED 2002-04-04 US disclosed
US-6251913-B1 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor ZENECA LIMITED (GB) 2001-06-26 US disclosed
EP-0971895-A1 HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR AstraZeneca AB (SE) 2000-01-19 EP disclosed
WO-1998043959-A1 HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR ZENECA LIMITED (GB) 1998-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040002-A1 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor MMP1, HCAR1, MMP13 CTSL 199/4885PKM 4253/4885L3MBTL1 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.